Karolinska University, Stockholm
Research in cancer therapy provides new insights
Published in Pharma Investments, Ventures and Law Weekly, July 17th, 2005
Study 1: NRAS gene suppression initiates melanoma cell apoptosis.
According to recent research from Sweden, "the majority of human melanomas harbor activating mutations in either the BRAF or NRAS gene. To date, the role of oncogenic NRAS in melanoma remains poorly defined and no current therapies are directed at specifically suppressing oncogenic NRAS in human melanoma tumors."
"The aim of our study, therefore, was to investigate the effects of suppressing oncogenic NRAS in human melanoma cell lines in vitro. Using both small interfering RNA-and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Arrowhead Research Corporation
Nanotech company revises commercialization strategy - Arrowhead Research Corporation
Nanotechnology firm completes warrant redemption - BioVeris Corporation
Diagnostics company reports loss of $0.27 per share - Biophan Technologies, Inc.
Patent allowed for solution to enhance image quality of MRI - CV Therapeutics, Inc.
Biopharmaceutical firm reports option grants - Caraco Pharmaceutical Laboratories, Ltd.
Pharmaceutical company reports 27% increase in sales - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
